Zydus Cadila and TLC to Market Drugs Used in Treating Black FungusThursday May 27, 2021 at 1:36 pm
On Wednesday, Zydus Cadila and TLC, a specialty pharmaceutical firm of Taiwan announced that they have come to an agreement regarding the marketing of Liposomal Amphotericin B, a critical medicine used in the treatment of mucormycosis (black fungus) in India.
Zydus Cadila stated that these two companies have signed a pact to publicize Ampho TLC (Amphotericin B Liposome for Injection 50mg) in India.
It stated that under the pact, TLC shall produce and supply AmphoTLC non-exclusively to Zydus, and Zydus in return shall take the responsibility of commercializing the medicine in India.
Sharvil Patel, the MD of Cadila Healthcare opined, “With India facing an acute shortage of the drug to treat mucormycosis, we are making this critical drug available in India on an immediate basis.”
He said that the current situation demands a safe and effective therapy.
George Yeh, the President of TLC stated, “…we will be delivering the first batch of Ampho TLC to India to help assuage the urgent need for one of the safest and most effective antifungal drugs very soon.”
Zydus Cadila exclaimed that the Central Drugs Standard Control Organization has given approval to TLC’s new drug application (NDA) for Amphotericin B Liposome for Injection 50mg for introducing it on an immediate basis according to the usage and indication that is approved.
It is of the opinion that amidst the rise in the number of black fungus cases in India, Ampho TLC shall aid in the shortage of acute Liposomal Amphotericin B in the country.
Mucormycosis, also termed as black fungus, is an acute fungal infection and this disease when it gets associated with Covid-19 turns out to be fatal, according to the statement.
It also said that Ampho TLC is a Liposomal Amphotericin B injection used in treating serious systemic fungal infections like mucormycosis.
The listed entity of Zydus Group, shares of Cadila Healthcare were trading on BSE at Rs 626.45 per scrip, which is more than 0.64 percent from the earlier close.